

## 2022 NLA Scientific Sessions Poster Hall Abstracts

Board Number	Date	Time	Abstract #	Name	Poster Title
1	6/3/2022	11:25AM-12:05PM	78	Amanda Guerin, BSc- Donald Hunninghake Familial Hypercholesterolemia Abstract Award Winner	Sex Disparities in the Treatment and Outcomes of Familial Hypercholesterolemia
	6/4/2022	10:10-11:00AM	78	Amanda Guerin, BSc- Donald Hunninghake Familial Hypercholesterolemia Abstract Award Winner	Sex Disparities in the Treatment and Outcomes of Familial Hypercholesterolemia
2	6/3/2022	11:25AM-11:42PM	54	Robert A. Wild, MD, MPH, PhD, NCMP, FNLA	Pregnancy-Induced Hypertension: The Potential Role of Cholesterol Crystals in the Maternal Decidua
	6/3/2022	11:48AM-12:05PM	46	Jason Lecocq, MD, MBA	Characterization of inclisiran use in real world: Prescription data from Germany
	6/4/2022	10:10-10:27AM	27	Peter P. Toth, MD, PhD, FNLA	A randomized study to evaluate the effect of an inclisiran first implementation strategy vs usual care in patients with ASCVD and elevated low-density lipoprotein cholesterol: rationale and design of the VICTORION-INITIATE trial
	6/4/2022	10:33-11:00AM	30	Alexandra Sykes, MD	Novel Use of Therapeutic Plasma Exchange and Evinacumab in a Patient with Homozygous Familial Hypercholesterolemia
3	6/3/2022	11:25-11:42AM	84	Richard Amoateng, MD	Cardiovascular Risk Factors in a True Incident MI Population
	6/3/2022	11:48AM-12:05PM	73	Ahmed A. Kolkailah, MD	Lipid-Lowering Therapy for Primary Prevention of Cardiovascular Disease: A Nationwide Analysis of 440,721 Patients
	6/4/2022	10:10-10:27AM	86	Iulia Iatan, MD	A Clinically Validated Genetic Screening for Familial Hypercholesterolemia in Quebec
	6/4/2022	10:33-11:00AM	79	Urh Groselj, MD- Oral Presenter	Universal Screening for Familial Hypercholesterolemia in Two Populations
4	6/3/2022	11:25-11:42AM	72	Sabyasachi Sen, MD	Mesenchymal Stromal Cell (MSC) Therapy Improve Nonalcoholic Fatty Liver Disease (NAFLD) in Long Term High Fat Diet (HFD) Induced Obesity (DIO) Mouse
	6/3/2022	11:48AM-12:05PM	89	Chad Morreale, DO	Acquired Chylomicronemia Due to Autoantibodies Against GPIHBP1
	6/4/2022	10:10-10:27AM	45	Maya Safarova, MD, PhD	Severe Hypertriglyceridemia as a Cause of Arterial Thrombosis with Peripheral Embolic Complications.

### 2022 NLA Scientific Sessions Poster Hall Abstracts

	6/4/2022	10:33-11:00AM	52	Spencer Weintraub, MD	Improvement in Housestaff Knowledge of Novel Antihyperglycemic Agents Through a Cross-Specialty Beyond Diabetes" Educational Initiative"
5	6/3/2022	11:25-11:42AM	82	Sohil Golwala, MD	Unique Case of Management of Severe Hypertriglyceridemia Secondary to Familial Chylomicronemia Syndrome
	6/3/2022	11:48AM-12:05PM	74	Sohil Golwala, MD- Young Investigator #4	Lipoprotein X Hyperlipidemia and its Complications in a Patient with Primary Sclerosing Cholangitis
	6/4/2022	10:10-10:27AM	26	R. Scott Wright, MD	Efficacy and Safety of Inclisiran in Patients with Established Cerebrovascular Disease: Pooled Post Hoc Analysis of the Phase 3 ORION-9, ORION-10, and ORION-11 Randomized Controlled Trials
	6/4/2022	10:33-11:00AM	85	Maya Safarova, MD, PhD	Intima-media thickness measured at the common-carotid artery in patients treated with lipoprotein apheresis
6	6/3/2022	11:25-11:42AM	32	Peter P. Toth, MD, PhD, FNLA	Safety and efficacy of bempedoic acid in patients with renal impairment
	6/4/2022	10:10-10:27AM	66	Kyeeun Park, MD	Racial Difference in Hypertriglyceridemia and Its Impact on Coronary Heart Diseases
	6/4/2022	10:33-11:00AM	16	R. Scott Wright, MD	Efficacy and safety of inclisiran in patients with polyvascular disease: pooled post hoc analysis of the phase 3 ORION-9, ORION-10, and ORION-11 randomized controlled trials
7	6/3/2022	11:25-11:42AM	40	Bryan Oronsky, PhD	The NLRP3 inhibitor and Nrf2 agonist, RRx-001, ameliorates non-alcoholic fatty liver disease in rats
	6/3/2022	11:48AM-12:05PM	61	Kyeeun Park, MD	Association between Metabolic Syndrome and Pulmonary Arterial Hypertension
	6/4/2022	10:10-10:27AM	37	R. Preston Mason, PhD	Eicosapentaenoic Acid (EPA) Modulates Expression of Inflammatory Proteins in Pulmonary Endothelial Cells following Exposure to Air Pollution Particles
	6/4/2022	10:33-11:00AM	60	Don P. Wilson, MD, FNLA	Does Cholesterol Screening in Prader Willi Syndrome Represent an Opportunity to Reduce Cardiovascular Disease Risk?
8	6/3/2022	11:25-11:42AM	68	Tara Shrout, MD, MSc	Association of coronary events with burden and distribution of coronary artery calcification: Results from the Multi-Ethnic Study of Atherosclerosis
	6/3/2022	11:48AM-12:05PM	67	Venkat Sanjay Manubolu, MD	Coronary Computed Tomography Angiography Evaluation of Plaque Morphology and its Relationship to HDL and Total Cholesterol to HDL Ratio
	6/4/2022	10:10-10:27AM	62	Sohil Golwala, MD	Management of atherogenic dyslipidemia in a patient with LDL discordance
	6/4/2022	10:33-11:00AM	76	Sohil Golwala, MD	Unveiling Compound Heterozygous Familial Hypercholesterolemia

### 2022 NLA Scientific Sessions Poster Hall Abstracts

9	6/3/2022	11:25-11:42AM	53	Matthew Ito, PharmD, CLS, FNLA - (Suvasini Lakshmanan, MD, Young Investigator #5)	Effects of Icosapent Ethyl on Plasma Ceramides and Coronary Plaque Progression in EVAPORATE trial
	6/3/2022	11:48AM-12:05PM	53	Matthew Ito, PharmD, CLS, FNLA -Suvasini Lakshmanan, MD	Effects of Icosapent ethyl on Plasma Ceramides and Coronary plaque progression in EVAPORATE trial
	6/4/2022	10:10-10:27AM	65	Loba Alam, MD- Young Investigator #2/Oral Presenter	A Novel ABCG8 Variant and Apo(A) Short Isoform Associated with Premature Atherosclerosis and Familial Hypercholesterolemia Phenocopy.
	6/4/2022	10:33-11:00AM	63	Loba Alam, MD- Young Investigator #3	Ketogenic Diets Exacerbating Hypercholesterolemia in APOE Variants and APOB Mutations-Potential Role for Measuring Intestinal Absorption of Lipids
10	6/3/2022	11:48AM-12:05PM	34	Michael D. Shapiro, DO, MCR, FNLA	Efficacy and Safety of Bempedoic Acid in Patients with Metabolic Syndrome
	6/4/2022	10:10-10:27AM	6	Liam Brunham, MD, FNLA	Genetic Architecture and Cardiovascular Risk of Familial Combined Hyperlipidemia
	6/4/2022	10:33-11:00AM	75	Laura Kukuc, MD	Intracoronary Thrombus in a Patient with Elevated Lp(a) Levels and COVID-19
11	6/3/2022	11:25-11:42AM	70	Edward Gill, MD, FNLA	Why are Patients Presenting with STEMI Already on Statin not Treated with Additional Aggressive Lipid lowering agents?
	6/3/2022	11:48AM-12:05PM	24	Laney K. Jones, PharmD, CLS, FNLA	Barriers and Facilitators to Identification, Cascade Testing, and Treatment for Familial Hypercholesterolemia: A Scoping Review
	6/4/2022	10:10-10:27AM	33	Keith C. Ferdinand, MD, FNLA	Safety and Efficacy of Bempedoic Acid in Patients with Hypertension
12	6/3/2022	11:25-11:42AM	71	Jordan Lindekens, BSN	A Complex Case: Patient with Elevated Lp(a) and Debilitating Stroke
	6/3/2022	11:48AM-12:05PM	77	Matthew Deshotels, MD	Genetic Testing for Hypertriglyceridemia in Academic Lipid Clinics - Implications for Precision Medicine
	6/4/2022	10:10-10:27AM	50	Avi Aronov, MD	Association of Systemic Inflammation with Lipid Profiles and Management in Patients with Rheumatoid Arthritis
	6/4/2022	10:33-11:00AM	48	Maheswaran Dhanasekaran, MBBS	Marked Hypoleptinemia Precedes Overt Fat Loss in Immune Checkpoint Inhibitor-induced Acquired Generalized Lipodystrophy
13	6/3/2022	11:25-11:42AM	39	Serge Korjian, MD	A Cross-Study Comparison Investigating the Effect of CSL112 (Apolipoprotein A-I [Human]) on Cholesterol Efflux Capacity (Encore ACC 2022)
	6/3/2022	11:48AM-12:05PM	35	Benny Amore, PhD	Pharmacokinetics, Pharmacodynamics, and Safety of Bempedoic Acid in a Phase 1 Clinical Trial in Healthy Japanese, Chinese, and White Subjects
	6/4/2022	10:10-10:27AM	56	Enhua Wang, MD, MSc	The Effect of Estrogen and Testosterone on Cholesterol Crystallization

### 2022 NLA Scientific Sessions Poster Hall Abstracts

	6/4/2022	10:33-11:00AM	64	Kyeeun Park, MD	Socioeconomic Disparities in Dyslipidemia and Associated Complications: From the Latest National Database
14	6/3/2022	11:25-11:42AM	42	Diane MacDougall, MS	Characterization of Lipoprotein(a) Measurement in a Large US Healthcare Dataset
	6/4/2022	10:10-10:27AM	69	Michael Fatuyi, MD	Rate of 30-day Readmission & Economic Burden of Patients with Acute Congestive Heart Failure with Co-existing Metabolic Syndrome.
15	6/3/2022	11:25-11:42AM	43	Christie M. Ballantyne, MD, FNLA	GOULD EDU: Primary Results of a Cluster-Randomized Trial of an Educational Intervention to Improve Guideline Adherence and Intensification of Lipid-Lowering Therapy
	6/3/2022	11:48AM - 12:05PM	79	Urh Groselj, MD- Oral Presenter	Universal screening for familial hypercholesterolemia in two populations
	6/4/2022	10:10-10:27AM	18	Nimai Patel, MD	Association Between Dietary Fat Content and Serum Lipoprotein(a) Level
16	6/3/2022	11:25-11:42AM	47	Armen Fstkchian, PharmD	Comparing Prescribing Practices of Statin Therapy in Atherosclerotic Cardiovascular Disease Patients with Varying Levels of Chronic Kidney Disease
18	6/3/2022	11:25AM-12:05PM	59	Juliette Logan, MD- Young Investigator #1/Oral Presenter	An Unsolved Case: FH or Sitosterolemia?
	6/4/2022	10:10-11:00AM	59	Juliette Logan, MD- Young Investigator #1/Oral Presenter	An Unsolved Case: FH or Sitosterolemia?